Trajectories and predictive significance of inflammatory parameters for clinical outcome in COVID–19 patients treated with tocilizumab
Infection · 2025
DOI: 10.1007/s15010-024-02375-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection, 2025. Verfasst von Alexander Killer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Mo…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, COVID-19 Drug Treatment, COVID-19, Inflammation. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts.
Abstract (Originalsprache)
Purpose
The IL-6 receptor inhibitor tocilizumab reduces mortality and morbidity in severe cases of COVID-19 through its effects on hyperinflammation and was approved as adjuvant therapy. Since tocilizumab changes the levels of inflammatory markers, we aimed to describe these changes in patients treated with tocilizumab, analyse their value in predicting death and bacterial superinfection and determine their influence on mortality rates.
Methods
A retrospective analysis of 76 patients who were treated with tocilizumab for severe COVID-19 in 2020 and 2021 was conducted. Inflammatory markers (IL-6, C-reactive protein (CRP), procalcitonin) were documented before and up to seven days after tocilizumab administration.
Results
The overall mortality was 25% and 53.8% in patients who required invasive respiratory support. Deceased patients had higher baseline IL-6 (p = 0.026) and peak IL-6 levels after tocilizumab vs those who survived (p < 0.0001). A peak IL-6 value > 1000 pg/dl after tocilizumab administration was a good predictor of mortality (AUC = 0.812). Of the deceased patients 41.1% had a renewed CRP increase after an initial decrease following tocilizumab administration, compared to 7.1% of the surviving patients (p = 0.0011). Documented bacterial superinfections were observed in 35.5% (27/76) of patients, of whom 48.1% (13/27) died.
Conclusion
CRP-decline and IL-6 increase after tocilizumab treatment occurs regularly. An increase of IL-6 levels exceeding tenfold of baseline IL-6 levels, an absolute peak of 1000 pg/ml or a renewed increase of CRP are associated with higher mortality. Suppressed CRP synthesis can impede the diagnosis of bacterial superinfections, thus increasing the risk for complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Moorenstraße 5, 40225, Düsseldorf, Germany.
- Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Moorenstraße 5, 40225, Düsseldorf, Germany. smaranda.gliga@med.uni-duess…
- Institute of Virology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
- Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine and I. Dep. of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Förderung
- Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
Zitieren
APA
Killer, A., Gliga, S., Massion, P., Ackermann, C., De Angelis, C., Flasshove, C., Freise, N., Lübke, N., Timm, J., Eberhardt, K. A., Bode, J., Jensen, B. O., Luedde, T., Orth, H. M., & Feldt, T. (2025). Trajectories and predictive significance of inflammatory parameters for clinical outcome in COVID–19 patients treated with tocilizumab. Infection. https://doi.org/10.1007/s15010-024-02375-x
Vancouver
Killer A, Gliga S, Massion P, Ackermann C, De Angelis C, Flasshove C, et al. Trajectories and predictive significance of inflammatory parameters for clinical outcome in COVID–19 patients treated with tocilizumab. Infection. 2025. doi:10.1007/s15010-024-02375-x
BibTeX
@article{Killer2025,
author = {Killer, Alexander and Gliga, Smaranda and Massion, Pascal and Ackermann, Carla and De Angelis, Clara and Flasshove, Charlotte and Freise, Noemi and Lübke, Nadine and Timm, Jörg and Eberhardt, Kirsten Alexandra and Bode, Johannes and Jensen, Björn-Erik Ole and Luedde, Tom and Orth, Hans Martin and Feldt, Torsten},
title = {Trajectories and predictive significance of inflammatory parameters for clinical outcome in COVID–19 patients treated with tocilizumab},
journal = {Infection},
year = {2025},
doi = {10.1007/s15010-024-02375-x}
}
EUVIMED